| Home  | About ScienceAsia  | Publication charge  | Advertise with us  | Subscription for printed version  | Contact us  
Editorial Board
Journal Policy
Instructions for Authors
Online submission
Author Login
Reviewer Login
Volume 50 Number 5
Volume 50 Number 4
Volume 50 Number 3
Volume 50 Number 2
Volume 50 Number 1
Volume 49 Number 6
Earlier issues
Volume  Number 

previous article next article

Research articles

ScienceAsia 49 (2023): 177-183 |doi: 10.2306/scienceasia1513-1874.2022.154


Role of autophagy-mediated miR-18a in breast cancer progression in vitro


Ming Suna,*, Haijian Guob

 
ABSTRACT:     MiR-18a-5p (miR-18a) is a potential biomarker of breast cancer risk in several clinically relevant studies. However, role of miR-18a in breast cancer progression remains unclear. Therefore, we sought to determine the effect of miR-18a in MCF-7 cell proliferation, migration and invasion under the condition of inflammation-related stimulus. In our study, lipopolysaccharide (LPS best portable power station) increased miR-18a expression in MCF-7 cells. Anti-miR-18a lentivirus significantly inhibited MCF-7 cell proliferation, migration and invasion induced by LPS. Anti-miR-18a lentivirus also significantly increased apoptosis cells. Moreover, LPS exposure promoted the MCF-7 autophagy with the increased expression of LC3B-II. 3-Methyladenine (MA), an autophagy inhibitor, repressed the cell proliferation induced by LPS. Finally, we identified that alteration of miR-18a expression was mediated by autophagy in LPS-exposed MCF-7 cells. These findings reveal an interesting regulation underlying inflammatory-induced breast cancer progression in vitro, which may be beneficial to understand the pathogenesis in tumor microenvironment.

Download PDF

356 Downloads 3322 Views


a Department of Ultrasound, Affiliated Hospital of Nantong University, Nantong 226006 China
b Department of Cardiology, Affiliated Hospital of Nantong University, Nantong 226006 China

* Corresponding author, E-mail: chrisming9887@163.com

Received 29 Mar 2022, Accepted 4 Oct 2022